OBJECTIVE:To systematically evaluate the efficacy and safety of Chinese herbal medicine(CHM) combined with conventional Western Medicine(CWM) on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) base...OBJECTIVE:To systematically evaluate the efficacy and safety of Chinese herbal medicine(CHM) combined with conventional Western Medicine(CWM) on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) based on high-quality randomized placebocontrolled trials.METHODS:We searched PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure Database,Chinese Biomedical Literature Database,China Science and Technology Journal Database,and Wanfang databases for randomized placebo-controlled trials of CHM treatment for AECOPD from inception to June 4,2021.The Cochrane Collaboration’s tool and the Grading of Recommendations,Assessment,Development and Evaluation were used to assess the risk of bias and the evidence quality of the included studies.Revman 5.3 software was used for Meta-analysis.RESULTS:A total of 9 trials involving 1591 patients were included.The Meta-analysis showed that based on CWM treatment,CHM group had significant advantages over the placebo group in ameliorating clinical total effective rate [RR = 1.29,95% CI(1.07,1.56),P = 0.007,low quality] and TCM symptom scores [MD =-2.99,95% CI(-4.46,-1.53),P < 0.0001,moderate quality],improving arterial blood gas results [PaO_(2):MD = 4.51,95% CI(1.97,7.04),P = 0.0005,moderate quality;PaCO_(2):MD =-2.87,95% CI(-4.28,-1.46),P < 0.0001,moderate quality],reducing CAT scores [MD =-2.08,95% CI(-2.85,-1.31),P < 0.000 01,moderate quality],length of hospitalization [MD =-1.87,95% CI(-3.33,-0.42),P = 0.01,moderate quality],and acute exacerbation rate [RR = 0.60,95% CI(0.43,0.83),P = 0.002,moderate quality].No serious CHM-related adverse events were reported.CONCLUSIONS:The current evidence indicates that CHM is an effective and well-tolerated adjunct therapy for AECOPD patients receiving CWM.However,considering the high heterogeneity,this conclusion requires confirmation.展开更多
目的评价中国大陆中文期刊发表的中医药单病例随机对照试验(N-of-1试验)的报告质量。方法系统检索中国生物医学文献数据库、万方数字化期刊全文数据、中国知网、维普中文期刊数据库,收集中国大陆中文期刊发表的中医药N-of-1试验。由2名...目的评价中国大陆中文期刊发表的中医药单病例随机对照试验(N-of-1试验)的报告质量。方法系统检索中国生物医学文献数据库、万方数字化期刊全文数据、中国知网、维普中文期刊数据库,收集中国大陆中文期刊发表的中医药N-of-1试验。由2名研究者独立筛选文献和提取资料,并应用中医药单病例随机对照试验的报告规范(CENT for TCM)声明评价纳入研究的报告质量。结果共纳入11篇中医药N-of-1试验文献。CENT for TCM声明的领域1 (标题/摘要/关键词)充分报告比例最高,达84. 85%;领域6 (其他信息)充分报告比例最低为0,未报告比例为96. 97%;领域2 (引言)部分报告比例最高,为57. 58%。多个领域的报告情况存在不足。结论中医药N-of-1试验存在报告欠充分情况,未来建议严格按照CENT for TCM声明进行报告,并加强方法学设计、质量控制,以产出更加规范、透明、高质量的临床证据。展开更多
基金Supported by the National Natural Science:Research on Key Technology of Outcome Measurement and Evaluation of Syndrome Differentiation and Treatment Based on Clinical Trials of COPD (No. 81830116)the Chinese Medicine Inheritance and Innovation “Hundred and Ten Million” Talent ProjectChief Scientist of Qi-Huang Project [(2020) No. 219]the Zhong-yuan Scholars and Scientists Project (No. 2018204)。
文摘OBJECTIVE:To systematically evaluate the efficacy and safety of Chinese herbal medicine(CHM) combined with conventional Western Medicine(CWM) on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) based on high-quality randomized placebocontrolled trials.METHODS:We searched PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure Database,Chinese Biomedical Literature Database,China Science and Technology Journal Database,and Wanfang databases for randomized placebo-controlled trials of CHM treatment for AECOPD from inception to June 4,2021.The Cochrane Collaboration’s tool and the Grading of Recommendations,Assessment,Development and Evaluation were used to assess the risk of bias and the evidence quality of the included studies.Revman 5.3 software was used for Meta-analysis.RESULTS:A total of 9 trials involving 1591 patients were included.The Meta-analysis showed that based on CWM treatment,CHM group had significant advantages over the placebo group in ameliorating clinical total effective rate [RR = 1.29,95% CI(1.07,1.56),P = 0.007,low quality] and TCM symptom scores [MD =-2.99,95% CI(-4.46,-1.53),P < 0.0001,moderate quality],improving arterial blood gas results [PaO_(2):MD = 4.51,95% CI(1.97,7.04),P = 0.0005,moderate quality;PaCO_(2):MD =-2.87,95% CI(-4.28,-1.46),P < 0.0001,moderate quality],reducing CAT scores [MD =-2.08,95% CI(-2.85,-1.31),P < 0.000 01,moderate quality],length of hospitalization [MD =-1.87,95% CI(-3.33,-0.42),P = 0.01,moderate quality],and acute exacerbation rate [RR = 0.60,95% CI(0.43,0.83),P = 0.002,moderate quality].No serious CHM-related adverse events were reported.CONCLUSIONS:The current evidence indicates that CHM is an effective and well-tolerated adjunct therapy for AECOPD patients receiving CWM.However,considering the high heterogeneity,this conclusion requires confirmation.
文摘目的评价中国大陆中文期刊发表的中医药单病例随机对照试验(N-of-1试验)的报告质量。方法系统检索中国生物医学文献数据库、万方数字化期刊全文数据、中国知网、维普中文期刊数据库,收集中国大陆中文期刊发表的中医药N-of-1试验。由2名研究者独立筛选文献和提取资料,并应用中医药单病例随机对照试验的报告规范(CENT for TCM)声明评价纳入研究的报告质量。结果共纳入11篇中医药N-of-1试验文献。CENT for TCM声明的领域1 (标题/摘要/关键词)充分报告比例最高,达84. 85%;领域6 (其他信息)充分报告比例最低为0,未报告比例为96. 97%;领域2 (引言)部分报告比例最高,为57. 58%。多个领域的报告情况存在不足。结论中医药N-of-1试验存在报告欠充分情况,未来建议严格按照CENT for TCM声明进行报告,并加强方法学设计、质量控制,以产出更加规范、透明、高质量的临床证据。
